Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 3/20 | 0.59 |
| ▸ | MARS1 | P56192 | 1/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.58 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | SRC | P12931 | 2/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.58 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.58 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.58 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.58 |
| ▸ | LDHA | P00338 | 1/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.58 |
| ▸ | FBP1 | P09467 | 1/20 | 0.58 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.58 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.58 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10587115 | 1.00 | AHCY (0.59) | AHCYMARS1ADORA1P2RY1SMN1; SMN2 | |
| SCHEMBL19889158 | 0.92 | ALDH1A1 (0.65) | AHCYMARS1ADORA1P2RY1SMN1; SMN2 | |
| SCHEMBL8205660 | 0.92 | ALDH1A1 (0.65) | AHCYMARS1ADORA1P2RY1SMN1; SMN2 | |
| SCHEMBL31685764 | 0.92 | ALDH1A1 (0.65) | AHCYMARS1ADORA1P2RY1SMN1; SMN2 | |
| SCHEMBL10033986 | 0.92 | ALDH1A1 (0.65) | AHCYMARS1ADORA1P2RY1SMN1; SMN2 | |
| SCHEMBL23982402 | 0.92 | ALDH1A1 (0.65) | AHCYMARS1ADORA1P2RY1SMN1; SMN2 | |
| SCHEMBL11423681 | 0.92 | ALDH1A1 (0.65) | AHCYMARS1ADORA1P2RY1SMN1; SMN2 | |
| SCHEMBL13597931 | 0.92 | ALDH1A1 (0.65) | AHCYMARS1ADORA1P2RY1SMN1; SMN2 | |
| SCHEMBL4425824 | 0.92 | ALDH1A1 (0.65) | AHCYMARS1ADORA1P2RY1SMN1; SMN2 | |
| SCHEMBL5551928 | 0.90 | ADORA3 (0.69) | AHCYADORA1P2RY1SMN1; SMN2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699979-B2 | PREPARED VIA A STEREOSPECIFIC SN2 NUCLEOPHILIC ATTACK OF A PHOSPHODIESTER, OR PHOSPHOROTHIOATE, ON THE 3' POSITION OF A XYLONUCLEOTIDE; USEFUL IN ANTISENSE OR PROBE TECHNOLOGY | ISIS PHARMACEUTICALS, INC. | 2004-03-02 | — | — | US | disclosed |
| US-6500945-B2 | BIOSYNTHESIS; STEREOSPECIFIC | ISIS PHARMACEUTICALS, INC. | 2002-12-31 | — | — | US | disclosed |
| US-20020137921-A1 | Oligonucleotides having chiral phosphorus linkages | COOK PHILLIP DAN (US) | 2002-09-26 | — | — | US | disclosed |
| EP-0755255-A4 | TREATMENT OF TOXOPLASMOSIS | RES CORP TECHNOLOGIES INC (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-0655088-B1 | OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES | ISIS PHARMACEUTICALS INC (US) | 2002-07-24 | — | — | EP | disclosed |
| US-20010008936-A1 | Oligonucleotides having chiral phosphorus linkages | ISIS PHARMACEUTICALS, INC. | 2001-07-19 | — | — | US | disclosed |
| US-6239265-B1 | FOR RESEARCH AND DIAGNOSIS | ISIS PHARMACEUTICALS, INC. | 2001-05-29 | — | — | US | disclosed |
| US-5852188-A | Oligonucleotides having chiral phosphorus linkages | ISIS PHARMACEUTICALS, INC. (US) | 1998-12-22 | — | — | US | disclosed |
| US-5773424-A | PARASITICIDE | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-06-30 | — | — | US | disclosed |
| EP-0755255-A1 | TREATMENT OF TOXOPLASMOSIS | UNIVERSITY OF ALABAMA, BIRMINGHAM RESEARCH FOUNDATION (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1996018398-A1 | TREATMENT OF TOXOPLASMOSIS | THE UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION (US) | 1996-06-20 | — | — | WO | disclosed |
| US-5521302-A | NUCLEOPHILIC REACTION OF PHOSPHATE GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1996-05-28 | — | — | US | disclosed |
| EP-0655088-A1 | OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1995-05-31 | — | — | EP | disclosed |
| US-5212295-A | Monomers for preparation of oligonucleotides having chiral phosphorus linkages | ISIS PHARMACEUTICALS (US) | 1993-05-18 | — | — | US | disclosed |
| WO-1993008296-A1 | OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137921-A1 | Oligonucleotides having chiral phosphorus linkages | RNGTT, PNP, PSPH | AHCY 3532/4885MARS1 880/4885ADORA1 838/4885 |
| US-20010008936-A1 | Oligonucleotides having chiral phosphorus linkages | RNGTT, PNP, PSPH | AHCY 3532/4885MARS1 880/4885ADORA1 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.